The 2027 Medicare Part D national average monthly bid amount is $296.05, the base beneficiary premium is $41.33, and the Part D Premium Stabilization Demonstration ends December 31, 2026, returning standalone prescription drug plans to unsubsidized market pricing for CY2027 (CMS, July 2026). CMS ended the demo on the finding that plan sponsors now have year-one Inflation Reduction Act experience to price against, a shift the agency framed as sponsors having “sufficient experience under the redesigned Part D benefit” to support their bid assumptions.
The Three Numbers That Reset Standalone Drug Plan Pricing for 2027
The $296.05 national average monthly bid is a 24% increase over the 2026 level and the fourth consecutive year the bid has climbed more than 20% (Avalere, July 2026). The $41.33 base beneficiary premium is a 6% increase over the 2026 base of $38.99, held to that ceiling by the statutory Inflation Reduction Act cap that governs base-premium growth through CY2029 (InsuranceNewsNet, July 2026). Those two numbers together imply the direct federal subsidy per enrollee covers the difference between the bid and the beneficiary share, and the arithmetic reveals the size of the federal check the redesign now writes on the average PDP contract: roughly $254.72 per member per month before reinsurance and risk-sharing, before a single dollar of the demo subsidy is counted.
The demonstration itself paid out on top of that structure. Launched in CY2025 to smooth the transition into the redesigned benefit, the voluntary program cut the base beneficiary premium by $15 in 2025 and by $10 in 2026, capped year-over-year premium changes at $35 in 2025 and $50 in 2026, and layered a government risk corridor on top of the standard Part D reinsurance. Its two-year cost ran $9.8 billion (KFF, July 2026), and 99% of PDP enrollees were in a participating plan. The 2026 average standalone PDP premium was about $36 per month under the demo. Without it, the reference point every PDP has to underwrite around in 2027 is the unshielded base of $41.33 plus its own plan-specific bid variance to the national average.
| Metric | CY2025 (demo year 1) | CY2026 (demo year 2) | CY2027 (post-demo) |
|---|---|---|---|
| Base beneficiary premium | $36.78 (net of $15 cut) | $38.99 (net of $10 cut) | $41.33 |
| National average monthly bid | $179.45 | $239 (approx.) | $296.05 |
| YoY change cap on plan premiums | $35 | $50 | None (traditional pricing) |
| Government risk corridor overlay | Yes | Yes | No |
| Average PDP premium (weighted) | ~$28 | ~$36 | Plan-specific; final Sept 2026 |
What “Sufficient Experience” Means Inside a Pricing Cell
CMS’s rationale for ending the demonstration is that plan sponsors now have year-one claims experience under the redesigned benefit to feed into 2027 bids. That is a specific actuarial claim, not a policy statement. Under the redesigned benefit that took effect January 1, 2025, the coverage gap disappeared, the annual out-of-pocket cap fell to $2,000, and manufacturers began paying a discount in the initial and catastrophic phases in place of the old coverage-gap discount (Public Law 117-169, Inflation Reduction Act, August 2022). Every one of those changes rewrote a pricing cell that had been calibrated against a decade of pre-redesign experience. The CY2025 and CY2026 bids were built on projections; CY2027 is the first cycle sponsors have real, credibility-weighted claims data from the redesigned benefit to price against.
What changes inside the pricing model is the source of the assumption itself. In CY2025 and CY2026, a Part D pricing actuary building a claims-cost projection for the catastrophic phase had to work forward from pre-2025 experience adjusted for regulatory change, with the direction and magnitude of every adjustment carrying pure model risk. In CY2027, that same actuary is starting from CY2025 actual claims, then applying trend, drug-mix shift, and regulatory-change adjustments for CY2026 and CY2027 on top. That is the standard credibility ladder Part D pricing has always run on; it just could not run on real experience for the first two redesign years. The bid variance the industry saw in year one, with catastrophic phase utilization coming in materially above base cases, is exactly the kind of signal that would motivate a large adverse adjustment in a first-real-experience bid cycle, which is one plausible mechanic behind the 24% NAMBA jump this cycle after the 20-plus-percent jumps that preceded it.
The Change Cap and Adverse Selection
The demonstration’s $50 year-over-year change cap for CY2026 did more than moderate the sticker price a beneficiary saw at open enrollment. It suppressed the natural sorting mechanism that every voluntary insurance market runs on. When premiums cannot move by their true cost differential, plans that would have priced higher stay artificially cheap, plans that would have priced lower cannot advertise their advantage, and the healthy-life exits that ordinarily follow a real price spike do not happen at the pace the underlying cost trend would produce. Both of those channels are back in CY2027.
The re-emergence matters more for standalone PDPs than for the Medicare Advantage prescription drug benefit because the two products carry Part D through structurally different pricing machinery. A Medicare Advantage prescription drug plan (MA-PD) can offset a higher drug bid using rebate dollars generated by an efficient medical bid, which is how the segment funds the near-zero premiums that dominate marketing at Annual Enrollment. A standalone PDP has no medical bid, no rebate reservoir, and no cross-subsidy path; the drug bid recovery has to come from the drug premium and the direct federal subsidy alone. The demo compressed the visible price gap between the two segments. Its removal widens the gap again, exactly at the point in the cycle when the actuarial cost basis under the redesign is fully loaded into standalone PDP pricing.
Enrollment context frames the stakes. Roughly 25 million people are in a standalone PDP in 2026, up from 22.8 million in 2024, and the segment covers about half of the Part D-eligible Medicare population, with MA-PD covering most of the rest (KFF, 2026). Any share shift that follows the demo’s exit affects a pool that size. If even a modest slice of the healthier standalone PDP enrollees moves to MA-PD at open enrollment, the standalone risk pool concentrates on higher-morbidity lives, and the pricing signal from CY2027 experience feeds back into CY2028 bids at a stronger adverse-selection tilt than the CY2027 bids themselves already carry.
The Rebuttal on Cost, the Confirmation on Trend
CMS Administrator Mehmet Oz framed the shutdown as a cost decision. His statement that “The Biden admin gave BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies” (Healthcare Dive, July 2026) tracks the two-year $9.8 billion figure that KFF reported. The actuarial signal underneath the cost claim is separate: the demo removed the volatility that would have triggered its own adverse selection, but it also removed the market’s ordinary price-discovery function. Both readings, the political-cost read and the market-mechanics read, point at the same 2027 pricing behavior, which is why the transition is happening on the timing CMS chose rather than being pushed further out.
Avalere’s read that the change “could put further upward pressure on PDP premiums for 2028” (Avalere, July 2026) is consistent with the credibility mechanic above: CY2027 becomes the first fully unsubsidized standalone PDP experience year under the redesign, and CY2028 bids will price against that experience once it lands. If the demo’s exit produces a materially different mix shift than sponsors assumed in CY2027, the CY2028 pricing cycle will absorb that variance the same way CY2027 is now absorbing the year-one utilization variance from CY2025.
The Base-Premium Cap Is Doing More Work Than the Headline Number Suggests
The 6% jump in the base beneficiary premium, from $38.99 to $41.33, sits well below the 24% jump in the national bid because the Inflation Reduction Act caps base-premium growth at 6% annually through CY2029, regardless of what the underlying bid does. Without that cap, the base premium would move roughly in line with the bid, and the beneficiary would see a $41.33 base become something closer to $48 or $49 for CY2027. The cap absorbs the delta into the federal subsidy, which is why the direct federal subsidy per enrollee climbs faster than the beneficiary’s premium every year the cap binds.
That transfer is where a lot of the future political durability of the redesign will be decided. Beneficiary-facing costs are the visible outcome; federal outlays under the direct subsidy formula are the actuarial consequence. The Congressional Budget Office has projected federal Part D spending trajectories that already assume this cap will keep binding, and the CY2027 numbers push in the direction the projections anticipated (CBO, March 2026). The demonstration’s exit does not affect that cap or the federal-subsidy path; it only affects how the plan-specific piece on top of the base premium behaves for the 25 million standalone PDP enrollees.
MA-PD Bundling Widens the Visible Price Gap
The competitive geometry that shapes open enrollment in a demo-off year runs through the bid structure of the two segments rather than the drug benefit itself. Medicare Advantage plans build a total-package bid that includes Part D and pull rebate dollars from the medical side to buy down the drug premium the enrollee sees. That is how large national MA carriers advertise $0 drug premiums on plans that carry a full Part D benefit; the drug cost is not zero, it is being paid with rebates. The average enrollee-facing MA-PD Part D premium sat at roughly $8 per month in 2026, versus about $36 for the average standalone PDP under the demo (KFF, 2026).
That gap widens in CY2027. With the demo off, the standalone PDP average premium moves toward the unsubsidized cost of the redesigned benefit, plus each plan’s own bid variance to the national average, plus whatever risk load its own year-one experience justifies. The MA-PD premium remains a rebate-funded number that depends on the medical bid rather than on drug costs directly. A rational cost-sensitive enrollee comparing the two products at October 2026 open enrollment will see a bigger sticker gap than any AEP since the redesign began, which is the mechanism through which a mix shift into MA-PD would actually happen. The mix shift, in turn, is the input that decides how CY2028 bids get built on both sides of the fence.
What Pricing Teams Are Doing Between Now and the September Filing
The July 28 release is preliminary. Plan-specific premium amounts land in September 2026, and open enrollment runs October 15 through December 7 (Medicare.gov, 2026). Between now and the September finalization, pricing teams on the standalone side are running the same sensitivity work every post-demo transition would require: what enrollee mix does the plan hold after the change cap comes off, what does the utilization curve look like when a healthier subset actually can leave, and how much of the CY2027 bid needs to carry a first-year adverse-selection load rather than being priced to steady-state assumptions.
The distributional read CMS supplied gives one shape of that answer: about 25% of enrollees see no change or a decrease, about 30% see less than a $10 monthly increase, and about 45% see an $11 to $20 increase in 2027 (InsuranceNewsNet, July 2026). That distribution is a bid-side output; whether it holds through the enrollment cycle depends on which of those enrollees actually stay in the standalone segment when the plan-specific numbers publish. The gap between the projected distribution and the realized post-AEP mix is the number that shows up as first-year experience variance in the CY2028 bids the industry will build a year from now.
What the July 28 release settled is that the Inflation Reduction Act redesign is now running on its own actuarial machinery rather than on a bridge subsidy. The $296.05 national bid, the $41.33 base premium, and the demo’s December 31, 2026 sunset are the terms under which standalone PDPs, MA-PD sponsors, and 25 million Part D enrollees enter the cycle. Every load-bearing assumption in the CY2027 bids traces back to how well year-one experience under the redesign generalizes to a market that no longer has a $50 change cap or a government risk corridor sitting on top of it, and the CY2028 filing season is where the industry will find out.
Further Reading
- Medicare Part D 2026: Year-One Redesign Data Flips Key Actuarial Assumptions
- CBO's $500B Part D Spending Gap and the Actuarial Read Behind It
- CMS 75% AMP Floor for MFP Products: What It Does to Part D IPAY 2029 Pricing
- CMS GLP-1 Bridge and the $50 Copay Actuarial Read for Part D
Sources
- Centers for Medicare & Medicaid Services, “Medicare Part D 2027 National Average Monthly Bid Amount Information,” CMS.gov, July 28, 2026
- Centers for Medicare & Medicaid Services, “July 28, 2026 Parts C & D Announcement,” CMS.gov, July 2026
- Avalere Health, “2027 NAMBA Signals Continued Market Pressures in Part D,” advisory.avalerehealth.com, July 2026
- KFF, “CMS’s Decision to End Temporary Subsidies to Medicare’s Stand-Alone Drug Plans Could Mean Larger Premium Increases for Some Beneficiaries Next Year,” KFF.org, July 2026
- KFF, “An Overview of the Medicare Part D Prescription Drug Benefit,” KFF.org, 2026
- KFF, “Medicare Advantage 2026 Spotlight: First Look,” KFF.org, 2026
- Healthcare Dive, “CMS to end subsidies for Medicare drug plan premiums,” HealthcareDive.com, July 2026
- InsuranceNewsNet, “CMS will discontinue Part D subsidies for 2027,” InsuranceNewsNet.com, July 2026
- Public Law 117-169, Inflation Reduction Act of 2022, Congress.gov, August 2022
- Congressional Budget Office, “The Budget and Economic Outlook: 2026 to 2036,” CBO.gov, March 2026
- Medicare.gov, “Joining a plan,” Medicare.gov, 2026